Copy to clipboard 
Alafair Biosciences announced the first clinical use of its VersaCoat Flowable Hydrogel (VersaCoat Tendon Protector, VersaCoat Nerve Protector) by two leading surgeons in lower and upper extremity procedures.
VersaCoat Flowable Hydrogel, developed from Alafair’s proprietary VersaCore Hydrogel Technology, uses the same collagen-free hyaluronic acid and alginate formulation as VersaWrap Hydrogel Sheet (VersaWrap Tendon Protector, VersaWrap Nerve Protector). VersaCore’s alginate bioresorbs to progressively expose bioavailable hyaluronic acid throughout the healing process. Both polymers fully bioresorb without leaving residual material, allowing tissue to return to its pre-injury state.
VersaCoat Flowable Hydrogel is designed to provide a conformable, bioresorbable, and tissue-adherent matrix to allow gliding and to limit postoperative soft tissue tethering. The novel syringe delivery allows precise placement onto delicate and hard-to-reach anatomy, expanding the benefits of the company’s clinically proven VersaCore Hydrogel Technology into anatomically complex surgical sites.
VersaCoat Flowable Hydrogel received FDA 510(k) clearance in July 2025 and is indicated for use as a bioresorbable, flowable soft-tissue protector in tendon and peripheral nerve procedures. The device complements the company’s VersaWrap Hydrogel Sheet, which has an established history of clinical use in a wide range of soft-tissue repairs.
Sarah Mayes, PhD, Chief Scientific Officer and Co-Founder of Alafair Biosciences,said, “With VersaCoat as the first syringe-deliverable soft-tissue protector, Alafair is setting the new standard for nerve and tendon protection in both open and minimally invasive procedures. This achievement reflects the dedication and ingenuity of our entire Product Innovation Team.”
Source: Alafair Biosciences, Inc.
Alafair Biosciences announced the first clinical use of its VersaCoat Flowable Hydrogel (VersaCoat Tendon Protector, VersaCoat Nerve Protector) by two leading surgeons in lower and upper extremity procedures.
VersaCoat Flowable Hydrogel, developed from Alafair's proprietary VersaCore Hydrogel Technology, uses the same collagen-free hyaluronic...
Alafair Biosciences announced the first clinical use of its VersaCoat Flowable Hydrogel (VersaCoat Tendon Protector, VersaCoat Nerve Protector) by two leading surgeons in lower and upper extremity procedures.
VersaCoat Flowable Hydrogel, developed from Alafair’s proprietary VersaCore Hydrogel Technology, uses the same collagen-free hyaluronic acid and alginate formulation as VersaWrap Hydrogel Sheet (VersaWrap Tendon Protector, VersaWrap Nerve Protector). VersaCore’s alginate bioresorbs to progressively expose bioavailable hyaluronic acid throughout the healing process. Both polymers fully bioresorb without leaving residual material, allowing tissue to return to its pre-injury state.
VersaCoat Flowable Hydrogel is designed to provide a conformable, bioresorbable, and tissue-adherent matrix to allow gliding and to limit postoperative soft tissue tethering. The novel syringe delivery allows precise placement onto delicate and hard-to-reach anatomy, expanding the benefits of the company’s clinically proven VersaCore Hydrogel Technology into anatomically complex surgical sites.
VersaCoat Flowable Hydrogel received FDA 510(k) clearance in July 2025 and is indicated for use as a bioresorbable, flowable soft-tissue protector in tendon and peripheral nerve procedures. The device complements the company’s VersaWrap Hydrogel Sheet, which has an established history of clinical use in a wide range of soft-tissue repairs.
Sarah Mayes, PhD, Chief Scientific Officer and Co-Founder of Alafair Biosciences,said, “With VersaCoat as the first syringe-deliverable soft-tissue protector, Alafair is setting the new standard for nerve and tendon protection in both open and minimally invasive procedures. This achievement reflects the dedication and ingenuity of our entire Product Innovation Team.”
Source: Alafair Biosciences, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
